首页 > 诊疗频道 > 特别策划 > 2015国际罕见病日专题 > 正文
综合
问医生

欧盟批准诺华MS药物Gilenya新标签

2015-02-27生物谷
分享到微信朋友圈

“扫一扫”分享

核心提示:欧盟委员会(EC)已批准扩大Gilenya用于复发缓解型多发性硬化症(RRMS)治疗的欧洲标签,将既往对至少一种疾病修饰疗法(DMT)(包括最新获批的DMTs)无响应的成人患者群体纳入该药的治疗范围。

  2014年6月9日讯 /生物谷BIOON/ --诺华(Novartis)6月9日宣布,欧盟委员会(EC)已批准扩大Gilenya用于复发缓解型多发性硬化症(RRMS)治疗的欧洲标签,将既往对至少一种疾病修饰疗法(DMT)(包括最新获批的DMTs)无响应的成人患者群体纳入该药的治疗范围。此前,Gilenya已获欧盟批准,用于对注射药物干扰素β治疗无响应的复发缓解型多发性硬化症(RRMS)患者以及病情迅速恶化的重度多发性硬化症(MS)患者的治疗。

  此次Gilenya扩大标签的获批,是基于自2011年3月首次获批后3年来的上市后(post-marketing)临床试验的长期疗效和安全性数据。目前,Gilenya已获80个国家批准,据估计,在临床试验及上市后试验中,有超过9.15万例患者接受了Gilenya的治疗。

  今年5月,诺华公布了在MS患者中开展的关键性FREEDOMS和FREEDOMS II期临床的新汇总分析,这些数据证实了Gilenya在横跨多发性硬化症(MS)4个关键衡量措施(复发率、MRI病变、脑容量损失、残疾进展)的一致性疗效,通过药物及疾病管理解决这4个衡量措施,对于改善MS患者的治疗过程至关重要。

  新的汇总数据表明,在过去一年中经过治疗的高疾病活动度MS患者群体,Gilenya在横跨以下衡量措施取得了显著的疗效:复发率:与安慰剂相比,Gilenya使复发率(按年化复发率计算)降低48%;MRI病变:与安慰剂相比,Gilenya使新的T2病变的形成降低69%;脑容量损失:与安慰剂相比,Gilenya使脑容量损失降低46%;残疾进展:采用严格的6个月残疾衡量,与安慰剂相比,Gilenya使残疾进展降低45%。

  关于Gilenya:

  Gilenya(fingolimod,芬戈莫德)是一种神经鞘氨醇1-磷酸受体调节剂,是获批用于多发性硬化症(MS)治疗的首个口服疾病修饰疗法(DMT),该药于2010年获FDA批准,于2011年获欧盟批准。(生物谷Bioon.com)

  英文原文:European Commission approves wider use of Gilenya (fingolimod), the first once-daily pill for multiple sclerosis

  Indication expansion means clinicians will now have the flexibility to switch patients not responding to an adequate course of at least one disease modifying treatment (DMT) to fingolimod as soon as considered appropriate

  Indication expansion consolidates favourable benefit/risk profile of once-daily pill fingolimod

  Frimley, 9 June 2014 – Novartis is delighted to announce that the European Commission has endorsed the Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the expanded use of Gilenya? (fingolimod) for adult patients with highly active relapsing-remitting multiple sclerosis (RRMS).1

  The indication expansion will now give clinicians the flexibility to use fingolimod in the highly active RRMS group, for patients needing to switch from interferons as well as glatiramer acetate and other DMTs.1

  Prior to the indication expansion, fingolimod was limited for use in those patients with highly active RRMS not responding to an interferon.2

  The European Commission approval was based on a favourable review of the long-term efficacy and safety data for fingolimod and comes three years after the initial licence was granted in March 2011.3 Fingolimod is now approved in 80 countries and it is estimated that more than 91,500 patients have been treated with fingolimod in clinical trials and in the post-marketing setting.4

  Fingolimod is the only established oral therapy approved by NICE for the treatment of highly active RRMS that is effective across four key measures of MS disease activity – relapses, MRI lesions, brain volume loss and disability progression.5,6

  Novartis will work with the relevant funding bodies to ensure that patients who meet these new criteria are able to access fingolimod in the near future.

  Notes to editors

  Fingolimod is a once-daily oral therapy indicated for appropriate people with highly active RRMS2

  To date, more than 91,500 patients have been treated with fingolimod in clinical trials and in the post-marketing setting4

  Fingolimod has been approved in 80 countries.4

  About Novartis

  Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

十年之内患上心血管病的风险有多高

扫码或关注微信公号jjkkxxg
回复【风险】即可测试
综合
分享到微信朋友圈

“扫一扫”分享

保存在桌面 放入收藏夹

请输入你需要发表的评论内容

确定

你的帐号还没实名认证
暂时无法发表评论

我要认证确定

您的评论发表成功!
评论需要审核才能正常显示

确定

在线咨询

(向医生免费提问)
答你所问,名医在线近距离。
精彩推荐 网友都爱看 猜你喜欢
  • 肿瘤的真相与误区
  • 谈骨论筋
  • 仁心
  • 健康新知
  • 健康有益事
  • 减肥达人秀
疾病热文排行 一周健康热点 资讯 专题 访谈 问答 女人要如何预防阴道炎的发生? 女人要如何预防阴道炎的发生?

女人除了怕不孕之后更怕的是一身妇科疾病缠身,怀孕的就那…… [详细]

针灸有奇效?专家告诉你“奇”在哪 针灸有奇效?专家告诉你“奇”在哪

在我国的中医院校经常能看到一批批外国医生围着中国医生学…… [详细]

宝宝哭不停?查查5原因 宝宝哭不停?查查5原因

宝宝哭的原因有哪些?有些刚出生几个月的宝宝莫名地哭泣,…… [详细]

脂肪肝如何治疗 脂肪肝患者如何治疗?

轻度脂肪肝一般多坚持一定量运动,少食动物内脏等过油食物…… [详细]

热点 百科 养生 疾病 推荐 热门问答

声明:39健康网登载此文出于传递更多信息之目的,并不意味着赞同其观点或证实其描述。文章内容仅供参考,具体治疗及选购请咨询医生或相关专业人士。

39健康网 - 中国优质医疗保健信息与在线健康服务平台 Copyright © 2000-2017 未经授权请勿转载 | 网站简介 | 人才招聘 | 联系我们 | 问题反馈